Liminatus Pharma (LIMN) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Liminatus Pharma (LIMN) right now is Lead anti-CD47 program: IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells. Revenue is $0 (no approved products). If that keeps playing out, the setup is favourable; the risk to it is liminatus carries the full stack of risks that define a distressed pre-revenue biotech. No one can predict where LIMN trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Liminatus Pharma (LIMN) higher?
1. Lead anti-CD47 program.
IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells. The company has announced plans to initiate a Phase 1 trial in advanced solid tumors, including non-small cell lung cancer. Positive early safety and signal data would be the main catalyst for the stock. CD47 is a well-studied but historically difficult target where several larger programs have struggled.
2. Pipeline breadth and the InnocsAI merger.
Beyond IBA101, Liminatus has described a Guanylyl Cyclase C cancer vaccine program and a planned acquisition of InnocsAI that would add CAR-T and antibody candidates, including a CD19xCD22 bivalent CAR-T cleared for an early-phase study in Korea. A wider pipeline spreads the bet across more shots on goal. It also adds complexity, integration risk, and likely large share issuance to fund and complete the deal.
3. Financing is the immediate driver.
With cash measured in low single-digit millions and a going concern warning, Liminatus depends on continued capital raises to operate. The February 2026 equity and warrant financing kept the lights on but was small. Each raise tends to come at depressed prices and dilutes existing holders, so the timing, size, and terms of the next financing matter more to the share price right now than any clinical readout.
4. Nasdaq listing as a binary overhang.
The company has received deficiency notices on minimum bid price and market value rules and a formal delisting determination, which it is appealing before a Nasdaq Hearings Panel. The appeal stays any suspension while it is heard. Regaining compliance, potentially through a reverse split or a higher market value, would remove a major overhang, while an unfavorable outcome could push the stock to over-the-counter markets and sharply reduce liquidity.
What could weigh on LIMN?
Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit near $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company faces an active Nasdaq delisting process, and continued financings, plus the share issuance tied to the proposed InnocsAI merger, point to heavy dilution. The stock trades as a sub-dollar micro-cap with low liquidity and high volatility, and a total loss is a realistic outcome.
How to think about a LIMN forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the LIMN guide and whether LIMN is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the LIMN outlook
The bottom line: what is driving Liminatus Pharma (LIMN) is Lead anti-CD47 program, with revenue at $0 (no approved products). If that keeps playing out the setup is favourable; the risk is liminatus carries the full stack of risks that define a distressed pre-revenue biotech. No one can predict the price, so treat any LIMN forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around LIMN with Walnut
Use Liminatus Pharma as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Liminatus Pharma (LIMN)?
+
No one can reliably predict where LIMN will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Liminatus Pharma higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive LIMN higher?
+
The main growth drivers are Lead anti-CD47 program; Pipeline breadth and the InnocsAI merger; Financing is the immediate driver. Whether they play out is the real question, not a guaranteed path.
What are the risks to LIMN?
+
Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit near $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company faces an active Nasdaq delisting process, and continued financings, plus the share issuance tied to the proposed InnocsAI merger, point to heavy dilution. The stock trades as a sub-dollar micro-cap with low liquidity and high volatility, and a total loss is a realistic outcome.
Will LIMN stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Liminatus Pharma's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is LIMN a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the LIMN "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.